Compare KEN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | AAPG |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | Singapore | China |
| Employees | N/A | 567 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2025 |
| Metric | KEN | AAPG |
|---|---|---|
| Price | $61.90 | $30.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | ★ 10.1K | 4.4K |
| Earning Date | 12-03-2025 | 11-19-2025 |
| Dividend Yield | ★ 7.83% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | ★ $803,304,000.00 | $54,524,554.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $368.64 |
| P/E Ratio | $6.69 | ★ N/A |
| Revenue Growth | ★ 8.15 | N/A |
| 52 Week Low | $27.10 | $16.50 |
| 52 Week High | $62.88 | $48.45 |
| Indicator | KEN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 42.17 |
| Support Level | $59.90 | $28.50 |
| Resistance Level | $62.68 | $32.96 |
| Average True Range (ATR) | 1.09 | 0.70 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 74.19 | 40.31 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.